Avandia (rosiglitazone): REMS – Risk of Cardiovascular Events

Audience: Endocrinology, Cardiology [UPDATED 02/04/2011] FDA notified healthcare professionals and patients that information on the cardiovascular risks (including heart attack) of rosiglitazone has been added to the physician labeling and patient…



No related posts.